Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Terminated 2Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Lymphoid 1

Conditions

Neoplasms 3Breast Neoplasms 2Solid Tumours 1Side-effect of Antibiotic 1Neoplasm Metastasis 1Multiple Myeloma 1Multiple Endocrine Neoplasia Type 1 1Lymphoma, Non-Hodgkin 1Lymphoma 1Long QT Syndrome 1Hot Flashes 1Hodgkin Disease 1Carcinoma, Renal Cell 1Bacteremia 1Advanced Breast Cancer 1

Interventions

Cyclophosphamide 282Rituximab 260Etoposide 161Filgrastim 155Vincristine 145Doxorubicin 134Prednisone 117Cytarabine 108Radiotherapy 102Peripheral Blood Stem Cell Transplantation 90Methotrexate 90fludarabine phosphate 87Melphalan 78Busulfan 71Dexamethasone 59Granulocyte Colony-Stimulating Factor 56Carmustine 53fludarabine 51Bortezomib 46Tacrolimus 44Mycophenolic Acid 41Antilymphocyte Serum 41Ifosfamide 40Leucovorin 39Gemcitabine 38Whole-Body Irradiation 36Cyclosporine 35Bendamustine Hydrochloride 34sargramostim 33Methylprednisolone 32

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Completed × Lymphoma × Moxifloxacin × Clear all
NCT01525394 2023-06-22

A Double-Blind Study in Healthy Volunteers to Assess the Effect of E7080 on the QTc Interval

Eisai Inc.

Phase 1 Completed
52 enrolled
Lymphoid

Lymphoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡